Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Acromegaly and Gigantism Drugs market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Acromegaly and Gigantism Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Acromegaly and Gigantism Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Ipsen
Novartis
Pfizer
By Type:
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1
By End-User:
Hospitals
Clinics
Others
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Acromegaly and Gigantism Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Somatostatin Analogs from 2016 to 2027
-
1.3.2 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of GH Receptor Antagonists from 2016 to 2027
-
1.3.3 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Dopamine Agonists from 2016 to 2027
-
1.3.4 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Recombinant Human IGF-1 from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027
-
1.4.2 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Clinics from 2016 to 2027
-
1.4.3 China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Acromegaly and Gigantism Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Acromegaly and Gigantism Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Somatostatin Analogs
-
3.4.2 Market Size and Growth Rate of GH Receptor Antagonists
-
3.4.3 Market Size and Growth Rate of Dopamine Agonists
-
3.4.4 Market Size and Growth Rate of Recombinant Human IGF-1
4 Segmentation of Acromegaly and Gigantism Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Acromegaly and Gigantism Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Acromegaly and Gigantism Drugs in Hospitals
-
4.4.2 Market Size and Growth Rate of Acromegaly and Gigantism Drugs in Clinics
-
4.4.3 Market Size and Growth Rate of Acromegaly and Gigantism Drugs in Others
5 Market Analysis by Regions
-
5.1 China Acromegaly and Gigantism Drugs Production Analysis by Regions
-
5.2 China Acromegaly and Gigantism Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Acromegaly and Gigantism Drugs Landscape Analysis
-
6.1 North China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
6.2 North China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
7 Central China Acromegaly and Gigantism Drugs Landscape Analysis
-
7.1 Central China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
7.2 Central China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
8 South China Acromegaly and Gigantism Drugs Landscape Analysis
-
8.1 South China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
8.2 South China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
9 East China Acromegaly and Gigantism Drugs Landscape Analysis
-
9.1 East China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
9.2 East China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
10 Northeast China Acromegaly and Gigantism Drugs Landscape Analysis
-
10.1 Northeast China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
10.2 Northeast China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
11 Southwest China Acromegaly and Gigantism Drugs Landscape Analysis
-
11.1 Southwest China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
11.2 Southwest China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
12 Northwest China Acromegaly and Gigantism Drugs Landscape Analysis
-
12.1 Northwest China Acromegaly and Gigantism Drugs Landscape Analysis by Major Types
-
12.2 Northwest China Acromegaly and Gigantism Drugs Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Ipsen
-
13.1.1 Ipsen Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Novartis
-
13.2.1 Novartis Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Pfizer
-
13.3.1 Pfizer Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Somatostatin Analogs from 2016 to 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of GH Receptor Antagonists from 2016 to 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Dopamine Agonists from 2016 to 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Recombinant Human IGF-1 from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Hospitals from 2016 to 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Clinics from 2016 to 2027
-
Figure China Acromegaly and Gigantism Drugs Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Acromegaly and Gigantism Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Acromegaly and Gigantism Drugs
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Acromegaly and Gigantism Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Acromegaly and Gigantism Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Somatostatin Analogs
-
Figure Market Size and Growth Rate of GH Receptor Antagonists
-
Figure Market Size and Growth Rate of Dopamine Agonists
-
Figure Market Size and Growth Rate of Recombinant Human IGF-1
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Acromegaly and Gigantism Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Acromegaly and Gigantism Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospitals
-
Figure Market Size and Growth Rate of Clinics
-
Figure Market Size and Growth Rate of Others
-
Table China Acromegaly and Gigantism Drugs Production by Regions
-
Table China Acromegaly and Gigantism Drugs Production Share by Regions
-
Figure China Acromegaly and Gigantism Drugs Production Share by Regions in 2016
-
Figure China Acromegaly and Gigantism Drugs Production Share by Regions in 2021
-
Figure China Acromegaly and Gigantism Drugs Production Share by Regions in 2027
-
Table China Acromegaly and Gigantism Drugs Consumption by Regions
-
Table China Acromegaly and Gigantism Drugs Consumption Share by Regions
-
Figure China Acromegaly and Gigantism Drugs Consumption Share by Regions in 2016
-
Figure China Acromegaly and Gigantism Drugs Consumption Share by Regions in 2021
-
Figure China Acromegaly and Gigantism Drugs Consumption Share by Regions in 2027
-
Table North China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table North China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table North China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table North China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure North China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table Central China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table Central China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table Central China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table Central China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure Central China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table South China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table South China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table South China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table South China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure South China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table East China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table East China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table East China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table East China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure East China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table Northeast China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table Northeast China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table Northeast China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure Northeast China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table Southwest China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table Southwest China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table Southwest China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table Southwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure Southwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table Northwest China Acromegaly and Gigantism Drugs Consumption by Types from 2016 to 2027
-
Table Northwest China Acromegaly and Gigantism Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2016
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2021
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by Types in 2027
-
Table Northwest China Acromegaly and Gigantism Drugs Consumption by End-Users from 2016 to 2027
-
Table Northwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2016
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2021
-
Figure Northwest China Acromegaly and Gigantism Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Ipsen
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ipsen
-
Figure Sales and Growth Rate Analysis of Ipsen
-
Figure Revenue and Market Share Analysis of Ipsen
-
Table Product and Service Introduction of Ipsen
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
Table Company Profile and Development Status of Pfizer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer
-
Figure Sales and Growth Rate Analysis of Pfizer
-
Figure Revenue and Market Share Analysis of Pfizer
-
Table Product and Service Introduction of Pfizer
-
